Antonio Antón

5.1k citations

61 papers · 2.1k indexed · h-index 21

Impact in

Otorhinolaryngology top 1%
- Head and Neck Cancer Studies
Oncology top 2%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies

Papers in ⓘ

Oncology 43
- Cancer Treatment and Pharmacology 22
- Colorectal Cancer Treatments and Studies 14
- HER2/EGFR in Cancer Research 10
- Lung Cancer Research Studies 7
Cancer Research 19
- Breast Cancer Treatment Studies 16

Co-authors: Alfredo Carrato (10 shared papers)Rosa Güell (6 shared papers)Á. Artal (6 shared papers)Bartomeu Massutí (6 shared papers)Rafael Rosell (3 shared papers)J. Sanchís (3 shared papers)I. Barneto (3 shared papers)Roberto Pazo-Cid (1 shared paper)
Journals: Journal of Clinical Oncology (18 papers)Clinical & Translational Oncology (3 papers)Anti-Cancer Drugs (3 papers)Cancer Research (3 papers)Cancer (2 papers)
Partner nations: Spain United Kingdom Italy

In The Last Decade

Antonio Antón

59 papers receiving 2.0k citations

Peers

Countries citing papers authored by Antonio Antón

Since Specialization

Citations

This map shows the geographic impact of Antonio Antón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Antón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Antón more than expected).

Fields of papers citing papers by Antonio Antón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Antón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Antón. The network helps show where Antonio Antón may publish in the future.

Co-authors

The 25 scholars most cited alongside Antonio Antón, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Antonio Antón Line = papers co-authored together Antonio Antón links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Felipe Cardenal, M.P. López-Cabrerizo, Antonio Antón, Vicente Alberola, Bartomeu Massutí, Alfredo Carrato, I. Barneto, M. Lomas, Margarita García, P. Lianes, Joaquín Montalar, Catalina Vadell, J.L. González-Larriba, Binh Nguyen, Á. Artal, Rafael Rosell	1999	389
2	Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer Journal of Clinical Oncology ·Ricardo Hitt, Antonio López–Pousa, Javier Martínez‐Trufero, V. Javier Escrig, Joan Carles, Alfredo Rizo, Dolores Isla, M. Eugenia Vega, Juan Luis Gomez Marti, Francisco S. N. Lobo, Pedro Pastor, Vicente Valentí, Joaquín Belón, Miguel A. Sánchez, C. Chaib, Cinta Pallarés, Antonio Antón, Andrés Cervantes, Luis Paz‐Ares, H. Cortés-Funes	2005	319
3	Predicting the Result of Noninvasive Ventilation in Severe Acute Exacerbations of Patients With Chronic Airflow Limitation CHEST Journal ·Antonio Antón, Rosa Güell, Juan Gómez Rivas, José Serrano, Abilio Castellano, Josep L. Carrasco, J. Sanchís	2000	147
4	Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study Cancer Research ·Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, Antonio Antón, Stefania Zambelli, Giampaolo Bianchini, Stefania Russo, Eva Ciruelos, R. Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, I. Maffeis, Pinuccia Valagussa, Giuseppe Viale	2020	109
5	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study Journal of Clinical Oncology ·Miguel Martín, Sibylle Loibl, Gϋnter von Minckwitz, Serafín Morales, Noelia Martínez-Jáñez, Ángel Guerrero, Antonio Antón, Bahriye Aktas, Winfried Schoenegg, Montserrat Muñoz-Mateu, José Á. García-Sáenz, Miguel Gil Gil, Manuel Ramos, Mireia Margelí Vila, Eva Carrasco, Cornelia Liedtke, Grischa Wachsmann, Keyur Mehta, Juan de la Haba-Rodríguez	2015	95
6	Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer Journal of Clinical Oncology ·Stephen Chan, Gilles Romieu, Jens Huober, T. Delozier, M. Tubiana-Hulin, Andreas Schneeweiß, Aňa Lluch, Antonio Llombart‐Cussac, Andreas du Bois, R. Kreienberg, José Mayordomo, Antonio Antón, M Harrison, Alison Jones, Eva Carrasco, A. Thareau Vaury, Bente Frimodt‐Moller, P. Fumoleau	2009	83
7	Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1 European Journal of Cancer ·Filippo Montemurro, Peter Ellis, Antonio Antón, Rachel Wuerstlein, Suzette Delaloge, Jacques Bonneterre, Nathalie Quénel-Tueux, Sabine C. Linn, Natsumi Irahara, Margarita Donica, Nicolas Lindegger, Carlos H. Barrios	2019	78
8	Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study Journal of Clinical Oncology ·Javier Sastre, Eugenio Marcuello, B. Masutti, Matilde Navarro, Silvia Gil, Antonio Antón, Albert Abad, Enrique Aranda, Joan Maurel, Manuel Valladares, I. Maestu, Alfredo Carrato, J. M. Vicent, Eduardo Díaz‐Rubio	2005	76
9	Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. PubMed ·Laura García‐Estévez, J. Cuevas, Antonio Antón, Jesús Florián, José Manuel López-Vega, Amalia Velasco, Francisco S. N. Lobo, Ana Herrero, José Fortes	2003	61
10	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer British Journal of Cancer ·Jesús García‐Foncillas, Josep Tabernero, Élena Elez, Enrique Aranda, Manuel Benavides, Carlos Camps, Eloísa Jantus‐Lewintre, Rafael López‐López, Laura Muinelo‐Romay, Clara Montagut, Antonio Antón, Guillermo López, Eduardo Díaz‐Rubio, Federico Rojo, Ana Vivancos	2018	59
11	Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance Breast Cancer Research and Treatment ·Héctor Hernández‐Vargas, Socorro Marıá Rodríguez-Pinilla, Mercedes Julián-Tendero, Pedro Sánchez‐Rovira, Cristóbal Cuevas, Antonio Antón, Maria Jesus Ríos, José Palacios, Gema Moreno‐Bueno	2006	59
12	Advanced HER2-positive gastric cancer: Current and future targeted therapies Critical Reviews in Oncology/Hematology ·Roberto Pazo-Cid, Antonio Antón	2012	51
13	Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study Journal of Clinical Oncology ·Stephen P. Ackland, Antonio Antón, G. P. Breitbach, E Colajori, Jennifer Tursi, C Delfino, Anna Efremidis, Adnan Ezzat, A. Fittipaldo, K Kolarić, Massimo Lopez, Donatella Viaro, (unknown)	2001	48
14	Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM) Breast Cancer Research and Treatment ·Carlos Jara Sánchez, Amparo Ruı́z, Miguel Martín, Antonio Antón, Blanca Munárriz, Arrate Plazaola, J. Schneider, Purificación Martínez del Prado, Emilio Alba, António Fernández	2006	42
15	Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. Journal of Clinical Oncology ·Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló, Audrey Hennequin, Adela Fernández, Marco Colleoni, Vicente Carañana, Vanesa Quiroga, Jacques Médioni, Vega Iranzo, Duncan Wheatley, Sonia Del Barco, Antonio Antón, Erion Dobi, Manuel Ruíz‐Borrego, Daniel Alcalá-López, Jhudit Pérez‐Escuredo, Miguel Sampayo-Cordero, José Manuel Pérez-García, Javier Cortés	2023	42
16	Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma International Journal of Radiation OncologyBiologyPhysics ·Fernando Rivera, Maica Galán, Josep Tabernero, Andrés Cervantes, M. E. Vega-Villegas, Javier Gállego, Berta Laquente, Edith Rodríguez, Alfredo Carrato, P. Escudero, Bartomeu Massutí, Vicente Alonso-Orduña, Adelaida Cardenal, A. Sáenz, J. Giralt, Ana Yuste, Antonio Antón, Enrique Aranda	2009	31
17	Acute Physiologic Effects of Nasal and Full-Face Masks During Noninvasive Positive-Pressure Ventilation in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease Respiratory Care ·Antonio Antón, Julia Tárrega, Jordi Giner, Rosa Güell, J. Sanchís	2003	29
18	Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma Cancer ·Albert Font, A Moyano, Jose M. Puerto, A. Trés, Carlos García Girón, I. Barneto, Antonio Antón, Jose J Sanchez, Ana Rosa Rubio Salvador, Rafael Rosell	1999	24
19	Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma Molecular and Clinical Oncology ·Ana Cebollero, Teresa Puértolas, Isabel Pajares, Lourdes Calera, Antonio Antón	2016	23
20	Exemestane versus anastrozole as front‐line endocrine therapy in postmenopausal patients with hormone receptor‐positive, advanced breast cancer Cancer ·Antonio Llombart‐Cussac, Amparo Ruı́z, Antonio Antón, Agustí Barnadas, Silvia Antolín, José E. Alés‐Martínez, Isabel Álvarez, Raquel Andrés, José Á. García-Sáenz, Juan Lao, Eva Carrasco, Carmen Cámara, Isabel Casas, Miguel Martín	2011	23

About Antonio Antón

Antonio Antón is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Critical Care and Intensive Care Medicine and Hepatology, having authored 61 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (16 papers), Colorectal Cancer Treatments and Studies (14 papers), Advanced Breast Cancer Therapies (12 papers), HER2/EGFR in Cancer Research (10 papers), Gastric Cancer Management and Outcomes (7 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Otorhinolaryngology (289 citations), Oncology (1.4k citations), Pulmonary and Respiratory Medicine (1.0k citations), Cancer Research (451 citations) and Critical Care and Intensive Care Medicine (83 citations). Antonio Antón has collaborated with scholars based in Spain, United Kingdom and Italy. Frequent co-authors include Alfredo Carrato, Rosa Güell, Á. Artal, Bartomeu Massutí, Rafael Rosell, J. Sanchís, I. Barneto, Roberto Pazo-Cid, M. Lomas and Vicente Alberola. Their work appears in journals such as Journal of Clinical Oncology, Clinical & Translational Oncology, Anti-Cancer Drugs, Cancer Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact